Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Campath-1H in Children With Relapsed/Refractory ALL
NCT00089349Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Jul 2004
- Primary completion
- Sep 2006
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of alemtuzumab in acute lymphoblastic leukemia (ALL), sponsored by National Cancer Institute. Started Jul 2004; status: completed.
02
Drugs
alemtuzumab
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT00089349.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00089349.